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EDITORIAL
Red Blood Cell–Derived Nitric Oxide 
Bioactivity and Hypoxic Vasodilation
To β93 or not to β93?
Article, see p 2654
Hypoxic vasodilation is a conserved adaptive response that enables regional increases in blood flow to compensate for an acute reduction in oxygen delivery to tissues. Although already discovered in the 19th century, mecha-
nistic details of the underpinning signaling pathways have remained unresolved. 
Skeletal muscle blood flow and vascular conductance are more closely related to 
changes in arterial oxygen content than the partial pressure of oxygen, suggesting 
that the mechanisms involved in determining blood vessel diameter in the tissue 
are sensitive to changes in oxygen content. Because the latter is directly related to 
hemoglobin mass and oxygenation, red blood cells (RBCs) may be involved in sens-
ing the relationship between tissue oxygen demand and convective oxygen deliv-
ery when coupled to a transduction pathway capable of modulating blood flow.
S-NITROSO HEMOGLOBIN AND THE S-NITROSOTHIOL 
STORM
In 1996, Stamler’s group introduced a concept (Figure) that was as novel and in-
triguing as it was elegant, suggesting that RBCs have their own vasodilator mecha-
nism aboard while traveling the circulation,1 combining a capturing, preservation, 
and release mechanism for nitric oxide (NO) that is linked to hypoxic vasodilation2 
and platelet inhibition.3 Apart from RBCs being able to release NO, mechanistic 
details changed over time, and not all findings were reproducible by other groups.4
In this issue of Circulation, Sun et al5 present negative data from a joint effort by 
an international team of investigators that puts an end to the notion that Cysβ93 
S-nitrosothiol is involved in the process of hypoxic vasodilation. Sun et al’s data, 
however, are also positive in the sense that they confirm the ability of RBCs to 
export NO bioactivity.5 Is this the end of the S-nitroso hemoglobin story? Probably 
not, but most certainly for Cysβ93 S-nitrosothiol as a critical link.
HYPOXIC VASODILATION
Previous studies described an association between hypoxic vasodilation and the re-
lease of NO from isolated vascular tissue and cultured endothelial cells, and later 
demonstrated that NO is involved in hypoxic vasodilation in the human forearm. Of 
note, hypoxia has opposing effects on vascular diameter in the systemic circulation 
and the lung, where it causes vasoconstriction. This von Euler–Liljestrand mechanism 
matches regional pulmonary ventilation to perfusion, whereas regional vasodilation 
protects tissues in the face of reduced oxygen delivery. Enhanced NO production is 
a universal response to hypoxia,6 and elevated concentrations of NO metabolites 
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Figure. Cellular and enzymatic sources of nitric oxide (NO) bioactivity under normoxia and hypoxia.  
The SNO-Hb hypothesis postulated loading of endothelial-produced NO during transit through the venous circulation onto partially deoxygenated hemoglobin 
(Hb) to form HbNO, which hands over the NO group during passage through the lungs to an adjacent cysteine, specifically the SH group of cysteine-93 of the 
Hb β-chain to form a protein-bound S-nitrosothiol (Cysβ93-SNO), which would subsequently release its cargo on R-T transition in the microcirculation by using 
interaction with another protein thiol or glutathione. Alternatively, nitrite (NO2
–) entering red blood cells (RBCs) may react with deoxyHb or xanthine oxidoreduc-
tase (XOR), or arginine with endothelial NO synthase (eNOS) in competition with arginase to form NO bioactivity. Alternative cellular sources for NO2
– reduction 
under hypoxia include endothelial cells, smooth muscle cells, and surrounding target tissue (eg, cardiomyocytes). Several other NO2
–-reducing enzymes have been 
postulated and shown to be involved but are here omitted for the sake of clarity. GSH indicates glutathione; GS-NO, S-nitrosoglutathione; ROS, reactive oxygen 
species; R-T, oxy to deoxy; SH, sulfhydryl; and SNO-Hb, S-nitroso hemoglobin.
D
ow
nloaded from
 http://ahajournals.org by on N
ovem
ber 3, 2020
Schmidt and Feelisch Red Blood Cell NO and β93
ED
IT
OR
IA
L
June 4, 2019 Circulation. 2019;139:2664–2667. DOI: 10.1161/CIRCULATIONAHA.119.0404232666
have been detected in the blood of native highlanders 
and that of lowlanders trekking to high altitude. Here, 
NO plays a central role in rebalancing an acute mismatch 
between oxygen/energy supply and demand. Chronic 
environmental hypoxia requires multilevel adjustments in 
metabolism in addition to changes in vascular function 
and may differ from acute episodes of regional oxygen 
shortage. It may be worth reminding the reader that 
good hypoxia tolerance may have been part of our an-
cestral adult phenotype, and that mammalian embryo-
genesis and fetal growth occur in physiological hypoxia. 
Of course, not all vasodilation is NO mediated, and sev-
eral other mediators are involved in hypoxic vasodilation, 
including prostaglandins,7 adenosine triphosphate, and 
hydrogen sulfide.
NO BIOACTIVITY
Short-term hypoxic vasodilation appears to be mediated 
by bioactive NO metabolites rather than free NO.8 In-
deed, that RBCs release NO appears, at first sight, coun-
terintuitive, because they are also considered a sink for 
endothelium-derived NO via its rapid reaction with oxyhe-
moglobin (to form methemoglobin and nitrate), thereby 
limiting NO-induced vasodilation to its site of production. 
This, however, is only the case for free NO, and Sun and 
coworkers call the active principle released from RBCs 
NO bioactivity rather than NO. In biological systems, NO 
can bind to protein thiols in the form of an S-nitrosothiol 
and be transferred to a low-molecular-weight thiol by 
transnitrosylation (S-nitrosothiol pathway); formed S-
nitrosoglutathione may subsequently escape the RBC via 
a transporter. Alternatively, protein disulfide isomerase 
may facilitate the efflux of nitrite-derived S-nitrosothiols 
from RBCs. This complexity is reminiscent of the require-
ment of endothelial α-hemoglobin as an intermediate in 
NO signaling and early description of NO bioactivity as 
guanylyl cyclase–activating factor because of the chal-
lenges in detecting NO from NO synthase. More than 3 
decades after the discovery of endogenous NO forma-
tion, these complexities still confound the measurement 
of NO and NO adducts in complex biological systems, 
which is why their analysis often relies on bioactivity, 
pharmacological or genetic manipulation.
SOURCES OF NO BEYOND RBCS
In the presence of oxygen, NO is generated by the enzy-
matic conversion of l-arginine by NO synthases9; during 
hypoxia, nitrite is believed to function as an alternative 
source of NO and to be reduced by deoxyhemoglobin, 
xanthine oxidoreductase, aldehyde oxidase, and other 
enzymes.10 Nitrite originates from the conversion of di-
etary nitrate by the oral mucosal flora and oxidation of 
NO synthase –derived NO. Because anions cannot readily 
cross cell membranes and there is no concentration gradi-
ent of nitrite between plasma and RBCs, specific uptake 
and regulation mechanisms must be involved. Quantita-
tively, the hypoxic tissue rather than circulating blood cells 
appears to be the primary site of nitrite reduction. Thus, 
the present article by Sun et al5 may overestimate the rel-
ative contribution of RBC NO to hypoxic vasodilation, be-
cause the experiments were specifically designed to focus 
on this aspect. Blood-dependent nitrite reduction may be 
functionally more relevant for platelet inhibition.
EVEN WHEN BIASING TOWARD RBC-
NO, Β93C IS OF NO RELEVANCE FOR 
NO EXPORT
Sun et al studied βCys93Ala mutant mice (β93A) in 4 
distinct ex vivo and in vivo models designed to study the 
export of NO bioactivity from RBCs: a mouse Langen-
dorff heart model subjected to ischemia/reperfusion in-
jury in the absence or presence of RBCs pretreated with 
the arginase inhibitor, Nω-hydroxy-nor-l-arginine. Argi-
nase inhibitors are considered to enhance NO synthesis 
and, thus, exportable RBC NO bioactivity. As a point of 
concern, in rat aorta Nω-hydroxy-nor-l-arginine fails to 
prevent the tolerance to repeated applications of the 
endothelium-dependent agonist acetylcholine. The ef-
fects of isolated RBCs on platelet-rich plasma activation 
were studied, and isolated mouse/rat aorta were either 
exposed to Hb(NO)4 from β93C or β93A RBC hemoly-
sates, or pretreated with indomethacin and Nω-methyl-
l-arginine to block endogenous prostacyclin and NO for-
mation and then exposed to S-nitrosated RBCs. Finally, in 
β93C and β93A mice hypoxic (Fio2=0.1, arterial Po2 <40 
mm Hg) microvascular relaxation was studied in a dorsal 
skinfold window model. Whereas most of these models 
(except the latter) could be criticized for being nonphysi-
ological and highly biased toward enhancing any RBC-
NO–dependent effect, the fact that in all these models 
the β93A mutation was neutral strongly supports the 
authors’ main conclusion that RBCs are able to export 
NO, but that this capability is independent of β93C. It is 
surprising that the same mouse model was earlier inves-
tigated by the Stamler laboratory to conclude that β93C 
is (!) required for hypoxic vasodilation11 and cardiopro-
tection.12 However, no physiologically relevant hypoxic 
vasodilation appears to have been observed up to a Fio2 
of 0.1 in that study. Moreover, the observed enhanced 
cardiac injury and mortality of β93A mice subjected to 
myocardial infarction or heart failure12 may be explained 
by non–NO-related functions of βCys93 (see below). In 
conclusion, the S-nitroso hemoglobin hypothesis has to 
be considered rejected. But even if β93C plays no role in 
RBC-NO release, the cardiac phenotype of β93A mutant 
mice remains an important observation, which may be 
linked to one of the somewhat forgotten roles of β93C.
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FORGOTTEN ALTERNATIVE ROLES FOR 
Β93C
Indeed, β93C has several other important physiological 
functions (ie, in the allosteric transition of hemoglobin, 
the modulation of redox potential and oxygen affinity of 
the heme iron, inhibition of sickle fiber formation, and 
the hemoglobin disassembly pathway).13 β93C is situat-
ed at a critical position by neighboring with βAsp94, an 
important amino acid residue responsible for the Bohr 
effect and the heme-binding proximal histidine, βHis92. 
β93C appears to be critical in sustaining the intersubunit 
interactions at the α1/β2 (and α2/β1) interface via the salt 
bridge network, and this close association with heme-
heme signaling may explain its impact on heme activ-
ity and cooperative oxygen binding.13 Moreover, β93C 
protects heme and tissue from reactive oxygen species 
consistent with β93A mice showing enhanced levels of 
oxidative stress.14 These functions of β93C in oxygen 
handling and protection from oxidative stress may well 
explain the cardiac phenotype of βC93A mice.12
CLINICAL RELEVANCE OF RBC-NO
Irrespective of the different cellular (RBC versus tissue) 
and enzymatic sources, 2 relevant questions remain: Is 
hypoxic NO bioactivity of pathophysiological relevance 
(ie, are there patients with a dysfunctional hypoxic NO 
response and at particular risk of hypoxic organ dam-
age)? And, are there any realistic therapeutic options in 
treating hypoxic conditions by enhancing vasodilatory 
NO? There is some evidence that hypoxic vasodilation is 
impaired in older individuals and in patients with heart 
failure and obstructive sleep apnea.15 In humans, the S-
nitrosylating agent, ethyl nitrite, was found to increase 
RBC S-nitroso hemoglobin levels at reduced Fio2, cor-
recting hypoxia-induced deficits in tissue oxygenation, 
and to improve measures of oxygen utilization. In light 
of the present findings, however, the mechanism re-
mains unclear and may not have occurred via S-nitrosyl-
ation of ß93C because the compound lacks specificity. 
Another approach may be to enhance NO export from 
vascular cells by using arginase inhibitors. Time will tell.
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